New Hope Fertility Center failed to properly screen and test oocyte and semen donors for communicable diseases, FDA says.
What happened
FDA inspected the facility from November 1 to November 30, 2021 and documented significant deviations from rules for human cells, tissues, and cellular/tissue-based products (HCT/Ps). The letter says donors with Zika virus risk factors or missing screening answers were determined eligible, eligibility was sometimes determined before test results, and a donor with a reactive hepatitis B core antibody test was not made ineligible. FDA also cited missing donor eligibility documentation, untimely testing specimens, and inadequate labeling procedures, and said corrective actions after a 2014 warning letter were inadequate.
What FDA found
The firm determined oocyte donors eligible even when they reported Zika virus risk factors.
21 CFR 1271.75(d)The firm determined three oocyte donors eligible before receiving required communicable disease test results.
21 CFR 1271.50(a)Donor records for an anonymous oocyte donor and a directed semen donor lacked documentation that eligibility was determined.
21 CFR 1271.50(a)At least 25 anonymous oocyte donors were missing documentation of answers to required medical-history questions, and the Zika risk-country list in the questionnaire was incomplete.
21 CFR 1271.75(a)(1)A directed oocyte donor whose specimen was reactive for hepatitis B core antibody was not determined ineligible.
21 CFR 1271.80(d)(1)A communicable disease test specimen from a directed oocyte donor was not collected within the required time around oocyte recovery.
21 CFR 1271.80(b)
What FDA wants
FDA asks for a written response within 15 working days from receipt outlining specific corrections, supporting documentation, and how recurrence will be prevented; it also says reproductive tissue from donors with incomplete eligibility must stay in quarantine unless FDA grants an exemption.
Who should pay attention
- fertility clinics that screen or use donor oocytes, semen, or embryos
- tissue banks and assisted reproduction laboratories
- recipients of donor gametes or embryos and their clinicians
This is a summary. Read the original letter on fda.gov.